Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05615948 · ClinicalTrials.gov registry record · Phase 4
Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
A Phase 4 study, sponsored by Theresa Jacob, PhD, MPH.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT05615948 is a Phase 4 study that has completed, run by Theresa Jacob, PhD, MPH. The registered enrollment target is 15 participants.
The verdict
NCT05615948, a Phase 4 study, has completed, sponsored by Theresa Jacob, PhD, MPH.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.
Interventions
- DRUG VTS-K
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-12-06 |
| Est. Completion | 2024-05-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05615948
The ClinicalTrials.gov registry entry for NCT05615948 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theresa Jacob, PhD, MPH, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VTS-K is the first listed.
NCT05615948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05615948 about?
NCT05615948 is a clinical study titled "Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression". The purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.
What is the current status of trial NCT05615948?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2022-12-06. Estimated completion is 2024-05-17.
What interventions are being tested in trial NCT05615948?
The interventions under investigation include: VTS-K (DRUG).
Who is sponsoring clinical trial NCT05615948?
This trial is sponsored by Theresa Jacob, PhD, MPH, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.